Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07739043) titled 'NeuroRise: Intrathecal CE-1 Treatment for Traumatic SCI' on July 28.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label).
Primary Sponsor: Cell Therapy LLC
Condition:
SCI - Spinal Cord Injury
SCI
Spinal Cord Injury
Intervention:
Drug: Human allogeneic, culture expanded, UC-MSC
Recruitment Status: Not recruiting
Phase: Early Phase 1
Date of First Enrollment: September 2026
Target Sample Size: 8
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT07739043
Disc...